FDA Approves Emollient Foam for Atopic Dermatitis

Until now, people suffering from atopic dermatitis could do very little about the cracked, inflamed and dry skin associated with the disease. Dermatologists around the country have only been able to offer rich moisturizers and topical treatments to help keep the skin soft and moisturized. However, a recent product called HYLATOPIC has been designed specifically for patients with atopic dermatitis, and works at a deeper level by absorbing directly into the skin within seconds.

HYLATOPIC received FDA approval in 2009, and is an emollient foam designed to manage the burning, itching and pain associated with various types of dermatitis. The product has been developed by Onset  Therapeutics, a specialty pharmaceutical company that specializes in dermatology treatments, and is a non-steroidal prescription treatment that is now available in the United States.

The foam works by penetrating beneath the top layer of skin within seconds of application, and then creates a semi-permeable barrier that protects the skin against excessive water loss and irritants in the environment. For people suffering from atopic dermatitis, this means that the product acts as a shield against environmental toxins and also helps support the skin’s natural recovery process. With regular use, the patient can expect to achieve softer, healthier-looking skin.

Michael Heffernan, the President of Onset Therapeutics, explains: "It is well known that skin barrier dysfunction is a fundamental problem in atopic dermatitis patients. HYLATOPIC's 3-step approach to hydrate, protect and restore the natural skin barrier, combined with the aesthetic and safety elements which drive compliance, assists in helping our physicians achieve the best therapeutic outcomes."

HYLATOPIC can be used on any area of the body, and can be applied directly onto the skin using the fingertips. It does not leave any oil or residue behind, and can be applied under makeup and other skincare products.

(Source: MedicalNewsToday.com)

Further Reading

  • Up until now, dermatologists have been trying a variety of different skin removal techniques to get rid of precancerous skin lesions.

  • Topical agents, diet and certain medicines presented at the American Academy of Dermatology’s Summer Academy Meeting 2010 in Chicago is showing promise for preventing UV-induced skin cancer. Most skin cancers are caused by overexposure to ultraviolet radiation, and dermatologists are now encouraging the public to be conscientious about the amount of sun they are exposed to, and taking extra steps to use broad-spectrum sunscreen on a regular basis.

  • Individuals with a rare skin disease called recessive dystrophic epidermolysis bullosa (RDEB) can improve their condition with the transfer of bone marrow stem cells. A team of medical researchers has found that bone marrow stem cells can effectively treat the disease and help to repair the skin and speed up the healing process. This skin disease cannot be treated with conventional dermatology procedures.